These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21385899)

  • 1. Functional cooperation of RKTG with p53 in tumorigenesis and epithelial-mesenchymal transition.
    Jiang Y; Xie X; Li Z; Wang Z; Zhang Y; Ling ZQ; Pan Y; Wang Z; Chen Y
    Cancer Res; 2011 Apr; 71(8):2959-68. PubMed ID: 21385899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse.
    Xie X; Zhang Y; Jiang Y; Liu W; Ma H; Wang Z; Chen Y
    Carcinogenesis; 2008 Aug; 29(8):1632-8. PubMed ID: 18550569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial regulation of Raf kinase signaling by RKTG.
    Feng L; Xie X; Ding Q; Luo X; He J; Fan F; Liu W; Wang Z; Chen Y
    Proc Natl Acad Sci U S A; 2007 Sep; 104(36):14348-53. PubMed ID: 17724343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of CSN5 inhibits Ras-mediated tumorigenesis by inducing premature senescence in p53-null cells.
    Tsujimoto I; Yoshida A; Yoneda-Kato N; Kato JY
    FEBS Lett; 2012 Dec; 586(24):4326-31. PubMed ID: 23127558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.
    Greenhalgh DA; Wang XJ; Donehower LA; Roop DR
    Cancer Res; 1996 Oct; 56(19):4413-23. PubMed ID: 8813135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors.
    Sinha D; Wang Z; Ruchalski KL; Levine JS; Krishnan S; Lieberthal W; Schwartz JH; Borkan SC
    Am J Physiol Renal Physiol; 2005 Apr; 288(4):F703-13. PubMed ID: 15572521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
    Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
    Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL
    Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
    Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
    Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.
    Huber MA; Azoitei N; Baumann B; Grünert S; Sommer A; Pehamberger H; Kraut N; Beug H; Wirth T
    J Clin Invest; 2004 Aug; 114(4):569-81. PubMed ID: 15314694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes.
    Rinon A; Molchadsky A; Nathan E; Yovel G; Rotter V; Sarig R; Tzahor E
    Development; 2011 May; 138(9):1827-38. PubMed ID: 21447558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways.
    Larue L; Bellacosa A
    Oncogene; 2005 Nov; 24(50):7443-54. PubMed ID: 16288291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.
    Ha GH; Park JS; Breuer EK
    Cancer Lett; 2013 May; 332(1):63-73. PubMed ID: 23348690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.